|1.||Veys, Eric M: 7 articles (12/2005 - 03/2002)|
|2.||Mariette, Xavier: 6 articles (11/2012 - 03/2003)|
|3.||Wendling, Daniel: 6 articles (10/2012 - 01/2005)|
|4.||Kruithof, Elli: 6 articles (12/2005 - 03/2002)|
|5.||Baeten, Dominique: 6 articles (12/2005 - 03/2002)|
|6.||De Rycke, Leen: 6 articles (12/2005 - 04/2003)|
|7.||De Keyser, Filip: 6 articles (12/2005 - 04/2003)|
|8.||Berthelot, Jean-Marie: 5 articles (10/2012 - 03/2007)|
|9.||Goupille, Philippe: 4 articles (11/2012 - 01/2009)|
|10.||Dougados, Maxime: 3 articles (09/2014 - 03/2002)|
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/01/2002 - "Efficacy of tumor necrosis factor alpha blockade for enthesitis in spondylarthropathy: comment on the article by Marzo-Ortega et al."
01/01/2010 - "However, there is insufficient documented evidence, and long-term investigations are needed to define the possible protective mechanisms of TNFalpha inhibitor treatment in spondylarthropathies."
06/23/2007 - "Early treatment of patients with severe spondylarthropathy with TNFalpha-blocking agents may prevent structural damage and functional disability."
09/01/2005 - "Long-term follow-up in large populations of patients with spondylarthropathies is necessary to better define the benefit/risk/cost ratio of anti-TNFalpha drugs."
09/01/2005 - "Patients with active, severe and refractory spondylarthropathies are potential candidates for treatment with anti-TNFalpha drugs. "
|2.||TNFR-Fc fusion protein (etanercept)FDA Link
09/01/2001 - "Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study."
03/01/2007 - "Although this was not a double-blind, prospective, randomised study, the strong improvement noticed in the half-dose group suggests that etanercept 25 mg once a week can induce major clinical and biological relief in some patients with RA or spondylarthropathy."
03/01/2004 - "Ten patients classified to have uSpA according to modified European Spondylarthropathy Study Group criteria in a severe and active stage of disease were included in the study and received etanercept in a dosage of 25 mg two times a week for 12 weeks, followed by an observation period of 12 weeks. "
10/01/2012 - "Paradoxical IBD may occur during anti TNF-α therapy for inflammatory rheumatic disease, mostly in patients with spondylarthropathies while receiving etanercept, at a frequency estimated to 0.15% in the French patients with spondylarthropathies exposed to TNF-α antagonists. "
03/01/2007 - "Case records of all patients treated by etanercept for at least 6 months in the same rheumatology unit were retrospectively studied, to assess the mean values of DAS-28 and BASDAI, just before (J0), and after 6 months (M6) of treatment, in patients with rheumatoid arthritis or spondylarthropathy treated with etanercept 25 mg given either once or twice weekly. "
|3.||pamidronate (APD)FDA LinkGeneric
05/01/2006 - "Transient efficacy of pulse pamidronate treatment in active spondylarthropathies: an open study of 35 cases."
01/01/2005 - "Pamidronate has been tested in young-onset ankylosing spondylitis and spondylarthropathies with conflicting results but can be used in older patients without risk of major adverse effects. "
|5.||abatacept (BELATACEPT)FDA Link
03/01/2012 - "These fact sheets focus on several points: 1. in RA, initiation and monitoring of the abatacept treatment, management of patients with specific past histories, and specific clinical situations such as pregnancy 2. diseases other than RA, such as juvenile idiopathic arthritis, spondylarthropathies, or autoimmune diseases (systemic lupus erythematosus and other systemic autoimmune diseases) 3. models of letters for informing the rheumatologist and general practitioner 4. patient information about the use of abatacept in RA 5. and data on the new abatacept formulation for subcutaneous administration (approved by the FDA in August 2011 for patients with moderate-to-severe RA). "
01/01/2012 - "Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition."
|6.||Thalidomide (Thalomid)FDA Link
|8.||HLA-B27 Antigen (HLA B27 Antigen)IBA
11/01/2008 - "Of these 40 patients, 58% were HLA-B27 positive, and 98% met the European Spondylarthropathy Study Group criteria. "
06/01/1997 - "Cells of 34 HLA-B27 positive patients with SpA (fulfilling the European Spondylarthropathy Study Group criteria) and 26 HLA-B27 positive controls, all living in Java, Indonesia, were sampled. "
08/01/2008 - "Spondylarthropathies revolve around the strongest known contributing factor, HLA-B27. "
10/01/2005 - "Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies."
01/01/2004 - "The frequency and the distribution of HLA-B27 subtypes in spondylarthropathy (SpA) patients and controls were investigated in a sample Turkish population. "
|9.||infliximab (Remicade)FDA Link
03/01/2002 - "To confirm in a placebo-controlled trial the safety and efficacy profile of infliximab in short-term treatment of patients with active spondylarthropathy (SpA). "
07/01/2009 - "[Spondylarthropathy with Behçet's disease: response to infliximab]."
01/01/2009 - "Infliximab for treating axial spondylarthropathy in everyday practice."
07/01/2005 - "Low dose of infliximab is inadequate in most patients with spondylarthropathies."
04/01/2005 - "We used intraarticular infliximab to treat resistant knee monarthritis in a patient with spondylarthropathy. "
06/01/2011 - "In the case of established ReA, prolonged treatment of Chlamydia-induced ReA may be of benefit, not only in the case of acute ReA but also in those with chronic ReA or spondylarthropathy with evidence of persisting chlamydia antigens in the body. "
05/01/2007 - "In the HLA-B27-transgenic rat model of spondylarthropathy, mature B27 molecules expressed by DCs impair the formation of an antigen-independent immunologic synapse with naive CD4+ T cells by interfering with the engagement of costimulatory molecules. "
11/01/1998 - "The present classification of a number of arthropathies linked to the B27 antigen under the term spondylarthropathy emphasises the frequent familial aggregation and clustering during follow-up of these diseases. "
01/01/1998 - "In all of the three populations, a positive association of the B27 antigen with spondylarthropathies (SAPs) was revealed. "
11/01/1995 - "Although a T cell response driven by persisting bacterial antigen is still an attractive hypothesis, it does not explain all the known aspects of spondylarthropathy pathogenesis. "
08/01/1996 - "Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study."
05/01/1992 - "We report our experience with the use of corticosteroid injections into the sacroiliac joint in the treatment of patients with seronegative spondylarthropathy. "
01/01/2010 - "Later in the course of the disease, ultrasonography may help in diagnosing some peripheral complications (tendinous ruptures, synovial cysts, superficial bursitis...) and is useful to guide corticosteroid injections (RA, spondylarthropathies). "
06/23/2007 - "The treatment of spondylarthropathy comprises life-style advice, physical therapy, non-steroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, and local glucocorticoid injections. "
10/15/2001 - "Two women with spondylarthropathy involving very painful sacroiliac arthritis for 18 and 24 months had been relieved only transiently by several injections of steroids into the sacroiliac joint under fluoroscopy and by Bermuda casts. "
10/15/2001 - "Although successful arthrodesis of the sacroiliac joint had been reported previously for septic sacroiliitis, no report had shown the procedure to be effective for spondylarthropathy. "
10/15/2001 - "Possible use of arthrodesis for intractable sacroiliitis in spondylarthropathy: report of two cases."
05/28/2009 - "The correct recognition of spondylarthropathies needs an integrated multidisciplinary approach in order to identify common therapeutic strategies, especially in the era of the new biologic therapies."
09/15/2012 - "As a typical example, we have selected and summarise here key studies from the biomedical literature that focus on gene expression profiling of the response to biologic therapies in peripheral blood and biopsy samples in autoimmune diseases such as rheumatoid arthritis, spondylarthropathy, inflammatory bowel diseases and psoriasis. "
|4.||Renal Dialysis (Hemodialysis)
10/01/2001 - "[Erosive spondylarthropathy in hemodialysis. "
07/01/1990 - "A causal relationship between beta-2 microglobulin and hemodialysis spondylarthropathy has yet to be definitely established."
01/01/1990 - "This is an unusual location of destructive spondylarthropathy in a patient on chronic hemodialysis."
01/01/1990 - "Long term hemodialysis spondylarthropathy: an atlanto-occipital location."
10/01/1987 - "Since 1984, there have been several reports of a destructive spondylarthropathy occurring in patients who have received hemodialysis over a long period of time. "
|5.||Stem Cell Transplantation
09/01/2000 - "First manifestations of seronegative spondylarthropathy following autologous stem cell transplantation in HLA-B27-positive patients."
09/01/2000 - "The differential diagnosis of joint pain following autologous stem cell transplantation should include HLA-B27-associated spondylarthropathies in addition to the more commonly seen bone and joint pain due to immobilization and medication."